目次

Table of Content

1. Introduction To Spleen Tyrosine Kinase (SYK)
1.1 Overview of SYK Protein
1.2 SYK Signaling Pathways and Immune Regulation
1.3 Potential Of SYK As Drug Target

2. SYK Inhibitors - Mechanism Of Action

3. SYK Inhibitors Development and Clinical Trends By Indication
3.1 Autoimmune and Inflammatory Diseases
3.2 Cancer
3.3 Microbial Infections
3.4 Eye Diseases

4. Tavalisse - 1st Approved SYK Inhibitor
4.1 Overview and Patent Analysis
4.2 Pricing and Dosage Analysis
4.3 Sales Analysis

5. Global SYK Inhibitors Market Analysis
5.1 Current Market Scenario
5.2 Future Market Outlook

6. SYK Inhibitors Regional Market Analysis
6.1 US
6.2 China
6.3 Europe

7. Global SYK Inhibitors Clinical Pipeline Overview
7.1 By Country
7.2 By Indication
7.3 By Organization
7.4 By Phase

8. Global SYK Inhibitors Clinical Pipeline By Company, Indication and Phase
8.1 Research
8.2 Preclinical
8.3 Phase I
8.4 Phase I/II
8.5 Phase II
8.6 Phase III
8.7 Preregistration

9. Marketed SYK Inhibitor Clinical and Patent Insight

10. Global SYK Inhibitors Market Dynamics
10.1 Market Drivers and Opportunities
10.2 Market Restraints and Solutions

11. Competitive Landscape
11.1 Aptose Biosciences
11.2 CrystalGenomics
11.3 CSPC Ouyi Pharmaceutical
11.4 Formation Bio
11.5 Genosco
11.6 Hanmi Pharmaceutical
11.7 HUTCHMED
11.8 IACTA Pharmaceuticals
11.9 Ignota Labs
11.10 Rigel Pharmaceuticals

List of Figures & Tables
Figure 1-1: SYK Signaling In Immune and Non-Immune Cells
Figure 1-2: Biological and Pathological Effects Of SYK Activation
Figure 1-3: SYK: Key Discoveries and Milestones
Figure 1-4: SYK Domain Architecture
Figure 1-5: SYK Activation Mechanism
Figure 1-6: SYK - Multi-Disease Therapeutic Relevance
Figure 2-1: SYK Inhibition Mechanism
Figure 2-2: Mechanism Of Action Of SYK Inhibitors On Immune Signaling
Figure 3-1: SYK In Autoimmune and Inflammatory Diseases
Figure 3-2: Fostamatinib In ITP - Mode Of Action
Figure 3-3: C-935788-058 Phase 3 (NCT04138927) Study - Initiation and Completion Year
Figure 3-4: ESLIM-02 Phase 2/3 (NCT05535933) Study - Initiation and Completion Year
Figure 3-5: Pro00113327 Phase 1 (NCT06233110) Study - Initiation and Completion Year
Figure 3-6: Autoimmune and Inflammatory Diseases - SYK Inhibition Effects
Figure 3-7: SYK - Dual Role In Cancer
Figure 3-8: 810834 Phase 1 (NCT06639724) Study - Initiation and Completion Year
Figure 3-9: HM-FLTI-101 Phase 1/2 (NCT03850574) Study - Initiation and Completion Year
Figure 3-10: SYK - Mechanism In Immune Response To Pathogens
Figure 4-1: Fostamatinib - Approval Year By Country/Region
Figure 4-2: US - Price Per Unit and Supply (US$), November’2025
Figure 4-3: Europe - Price Per Unit and Supply (US$), November’2025
Figure 4-4: UK - Price Per Unit and Supply (US$), November’2025
Figure 4-5: Tavalisse - Initial and Increased Dose For The Treatment of Chronic Immune Thrombocytopenia (mg)
Figure 4-6: Global - Tavalisse Sales (US$ Million), 2020-2025
Figure 4-7: Global - Tavalisse Sales (US$ Million), Q1-Q3’2025
Figure 4-8: Global - Tavalisse Sales (US$ Million), Q1-Q4’2024
Figure 5-1: Global - SYK Inhibitors Sales (US$ Million), 2020-2025
Figure 5-2: Global - SYK Inhibitors Market Value (US$ Million), Q1-Q3’2025
Figure 5-3: Global - SYK Inhibitors Market Forecast (US$ Million), 2026 -2030
Figure 5-4: Global SYK Inhibitors Market - Future Opportunities
Figure 7-1: Global - Number Of SYK Inhibitors Clinical Trials By Country, 2025 Till 2030
Figure 7-2: Global - Number Of SYK Inhibitors Clinical Trials By Indication, 2025 Till 2030
Figure 7-3: Global - Number Of SYK Inhibitors Clinical Trials By Organization, 2025 Till 2030
Figure 7-4: Global - Number Of SYK Inhibitors Clinical Trials By Phase, 2025 Till 2030
Figure 10-1: Global SYK Inhibitors Market - Drivers and Opportunities
Table 1-1: SYK - Biological Role In Major Disease Areas
Table 3-1: SYK Inhibition In Microbial Infection - Potential Benefits
Table 3-2: SYK Inhibition In Ocular Disease Management
Table 4-1: Tavalisse - Dose Reduction Schedule
Table 4-2: Tavalisse - Recommended Dose Modifications and Management For Specific Adverse Reactions
Table 10-1: Global SYK Inhibitors Market - Restraints and Solutions